BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS) ($)
Form 8-K EX-99.1 Non-GAAP Reconciliation Tables
Latest, Q2 2026
3.84
Period ended Jun 30, 2026
Change on a year earlier
+70.7%
2.25 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS) ($) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3.84 | +70.7% | Form 8-K (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 3.24 | +165.6% | Form 8-K (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 1.95 | +1,200.0% | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 2.65 | +452.1% | Form 8-K (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 2.25 | +922.7% | Form 8-K (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 1.22 | -187.1% | Form 8-K (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 0.15 | – | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 0.48 | – | Form 8-K (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 0.22 | – | Form 8-K (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | -1.40 | – | Form 8-K (filed 2025-05-07) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS) ($), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj_eps_ads_diluted
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.